You are now leaving a Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) site. BIPI is not responsible for the way information is processed by sites linked to this one. Please review this site's privacy policy and terms of use to understand how your information will be processed. Linking to any other site is at your own risk.

  1. Home
  2. Resources

Resources

In addition to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. Not for type 1 diabetes or diabetic ketoacidosis.

For additional support, we've provided resources that include two types of tools: A glucose conversion guide for your practice, and for your patients, a daily tracker and lifestyle tips — which you can share during office visits. 

RESOURCES TO SHARE WITH YOUR PATIENTS

The following resources are designed to help your adult patients with type 2 diabetes. Encourage your patients to take advantage of these resources to help support them through their treatment.

 
VISIT TRADJENTA.COM
Direct your patients to tips and resources for a healthier lifestyle, including:
  • Healthy activities
  • Healthy eating tips
  • Meal makeovers
  • Recipes
 
Tradjenta savings and support
Help your eligible patients get the support they need by signing up for My TRADJENTA Support—which includes a savings card, helpful emails, and online tools.
 
TREATMENT TRACKER

A diet, medication, and exercise tracking tool that helps patients monitor their lifestyle and medication habits.

By providing a real-world glimpse into patients’ habits, this resource may help facilitate a productive, solution-oriented discussion for both you and your patients.

RESOURCES FOR YOUR PATIENTS

The following resources are meant to help you and your patients when treating type 2 diabetes.

Glucose Conversion Guide: Translate A1C into glucose

A1C to estimated average glucose (eAG conversion)1*†‡

eAG (mg/dL) = (A1C × 28.7) – 46.7
A1C (%) = (eAG + 46.7) ÷ 28.7

AIC into Glucose Level Conversion Chart

Download A Printable Version

*For educational purposes only.

†Data represent estimated averages.

‡Calculated estimated average glucose reflects values over the preceding 3 months.

 

Reference: 1. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-1478.

 

Other Resources

The following links contain an abundance of information and useful resources for your patients with type 2 diabetes.

StrategiesForChronicCare.com

A wide variety of tools and educational resources for patients are available on the Strategies for Chronic Care website.

AHA Diabetes Resources

The American Heart Association offers a wealth of helpful tools and resources for patients with type 2 diabetes.

CDC DIABETES CENTER

The Centers for Disease Control and Prevention provides a broad range of information, management tips, and resources specifically designed for people struggling with type 2 diabetes.

CVOT Results, Icon

View further evidence to reinforce your confidence in TRADJENTA

See the Results
 

Read about dosing for this single-strength DPP-4i for your adult patients with T2DM

See Dosing

Important Safety Information  

CONTRAINDICATIONS: Hypersensitivity to linagliptin or any of the excipients in TRADJENTA, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.

WARNINGS AND PRECAUTIONS

Pancreatitis: Acute pancreatitis, including fatal pancreatitis, has been reported in patients taking TRADJENTA. Take careful notice of potential signs and symptoms of pancreatitis and, if suspected, promptly discontinue and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using TRADJENTA.

Indication and Limitations of Use  

TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

TRADJENTA should not be used in patients with type 1 diabetes.

TRADJENTA has not been studied in patients with a history of pancreatitis, and it is unknown if using TRADJENTA increases the risk of developing pancreatitis in these patients.

Hypoglycemia: The use in combination with insulin or insulin secretagogues increases the risk of hypoglycemia. A lower dose of insulin or insulin secretagogue may be required.

Hypersensitivity Reactions: Discontinue TRADJENTA, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA.

Severe and Disabling Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider TRADJENTA as a possible cause for severe joint pain and/or disabling arthralgia and discontinue, if appropriate.

Bullous Pemphigoid: There have been reports of bullous pemphigoid requiring hospitalization. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue TRADJENTA.

Heart Failure: Heart failure has been observed with two other members of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Consider the risks and benefits of TRADJENTA in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment. Monitor patients for signs and symptoms. Advise patients of the symptoms of heart failure and to immediately report such symptoms. If heart failure develops consider discontinuation of TRADJENTA.

MOST COMMON ADVERSE REACTIONS (≥5%): Nasopharyngitis, hypoglycemia (when used in combination with sulfonylurea)

DRUG INTERACTIONS: The efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Alternative treatments should be used.

USE IN SPECIFIC POPULATIONS: Use during pregnancy only if clearly needed. Exercise caution when administering to a nursing woman.

CL-TJ-100054 04.22.2022

Please see Prescribing Information and Medication Guide.

Reference: 1. Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415.

 

Important Safety Information  

CONTRAINDICATIONS: Hypersensitivity to linagliptin or any of the excipients in TRADJENTA, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.

WARNINGS AND PRECAUTIONS

Pancreatitis: Acute pancreatitis, including fatal pancreatitis, has been reported in patients taking TRADJENTA. Take careful notice of potential signs and symptoms of pancreatitis and, if suspected, promptly discontinue and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using TRADJENTA.

Indication and Limitations of Use  

TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

TRADJENTA should not be used in patients with type 1 diabetes.

TRADJENTA has not been studied in patients with a history of pancreatitis, and it is unknown if using TRADJENTA increases the risk of developing pancreatitis in these patients.

Hypoglycemia: The use in combination with insulin or insulin secretagogues increases the risk of hypoglycemia. A lower dose of insulin or insulin secretagogue may be required.

Hypersensitivity Reactions: Discontinue TRADJENTA, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA.

Severe and Disabling Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider TRADJENTA as a possible cause for severe joint pain and/or disabling arthralgia and discontinue, if appropriate.

Bullous Pemphigoid: There have been reports of bullous pemphigoid requiring hospitalization. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue TRADJENTA.

Heart Failure: Heart failure has been observed with two other members of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Consider the risks and benefits of TRADJENTA in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment. Monitor patients for signs and symptoms. Advise patients of the symptoms of heart failure and to immediately report such symptoms. If heart failure develops consider discontinuation of TRADJENTA.

MOST COMMON ADVERSE REACTIONS (≥5%): Nasopharyngitis, hypoglycemia (when used in combination with sulfonylurea)

DRUG INTERACTIONS: The efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Alternative treatments should be used.

USE IN SPECIFIC POPULATIONS: Use during pregnancy only if clearly needed. Exercise caution when administering to a nursing woman.

CL-TJ-100054 04.22.2022

Please see Prescribing Information and Medication Guide.